Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
19.09
+0.65 (3.52%)
At close: Mar 27, 2026
SHE:300497 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | - | 695.35 | 729.37 | 978.03 | 1,272 |
Trading Asset Securities | - | 2.19 | 2.19 | 49.74 | 150.76 |
Cash & Short-Term Investments | 634.71 | 697.54 | 731.56 | 1,028 | 1,423 |
Cash Growth | -9.01% | -4.65% | -28.82% | -27.79% | -15.88% |
Accounts Receivable | - | 498.16 | 572.92 | 552.49 | 376.21 |
Other Receivables | - | 53.85 | 128.31 | 78.21 | 80.01 |
Receivables | - | 552.01 | 701.23 | 630.71 | 456.22 |
Inventory | - | 421.05 | 434.68 | 553.69 | 416.15 |
Other Current Assets | - | 10.42 | 9.97 | 17.11 | 15.97 |
Total Current Assets | - | 1,681 | 1,877 | 2,229 | 2,312 |
Property, Plant & Equipment | - | 2,267 | 2,331 | 2,201 | 1,857 |
Long-Term Investments | - | 255.9 | 271.27 | 271.42 | 133.02 |
Goodwill | - | - | - | 1.15 | 2.22 |
Other Intangible Assets | - | 235 | 241.07 | 249.71 | 256.32 |
Long-Term Deferred Tax Assets | - | 37.26 | 29.37 | 28.49 | 27.54 |
Other Long-Term Assets | - | 60.95 | 69.13 | 78.79 | 90.82 |
Total Assets | - | 4,537 | 4,819 | 5,060 | 4,678 |
Accounts Payable | - | 603.37 | 581.93 | 656.67 | 517.05 |
Accrued Expenses | - | 44.05 | 44.52 | 42.4 | 51.97 |
Short-Term Debt | - | 556.4 | 549.83 | 366.74 | 615.18 |
Current Portion of Long-Term Debt | - | 311.78 | 78.78 | 7.96 | 33.5 |
Current Income Taxes Payable | - | 0.05 | 0.82 | 8.71 | 13.89 |
Current Unearned Revenue | - | 2.72 | 3.4 | 1.42 | 1.82 |
Other Current Liabilities | - | 25.46 | 26.32 | 174.96 | 126.56 |
Total Current Liabilities | - | 1,544 | 1,286 | 1,259 | 1,360 |
Long-Term Debt | - | 736.48 | 998.26 | 1,043 | 353 |
Long-Term Unearned Revenue | - | 77.67 | 62.39 | 62.03 | 50.3 |
Long-Term Deferred Tax Liabilities | - | 1.96 | 2.05 | 6.27 | 3.92 |
Total Liabilities | - | 2,360 | 2,348 | 2,370 | 1,767 |
Common Stock | - | 550 | 550 | 550 | 550 |
Additional Paid-In Capital | - | 1,381 | 1,414 | 1,408 | 1,406 |
Retained Earnings | - | 408.78 | 680.88 | 881.68 | 1,023 |
Treasury Stock | - | -174.86 | -174.86 | -174.86 | -105.11 |
Comprehensive Income & Other | - | 15.45 | 14.3 | 16.89 | 6.08 |
Total Common Equity | 2,149 | 2,180 | 2,485 | 2,681 | 2,880 |
Minority Interest | - | -3.54 | -14.06 | 8.4 | 31.1 |
Shareholders' Equity | 2,168 | 2,177 | 2,471 | 2,690 | 2,911 |
Total Liabilities & Equity | - | 4,537 | 4,819 | 5,060 | 4,678 |
Total Debt | 1,722 | 1,605 | 1,627 | 1,418 | 1,002 |
Net Cash (Debt) | -1,087 | -907.13 | -895.31 | -389.97 | 421.54 |
Net Cash Growth | - | - | - | - | -66.26% |
Net Cash Per Share | -2.05 | -1.70 | -1.65 | -0.72 | 0.78 |
Filing Date Shares Outstanding | 553.92 | 538.65 | 538.65 | 538.65 | 538.65 |
Total Common Shares Outstanding | 553.92 | 538.65 | 538.65 | 538.65 | 543.13 |
Working Capital | - | 137.2 | 591.84 | 970.42 | 951.59 |
Book Value Per Share | 3.99 | 4.05 | 4.61 | 4.98 | 5.30 |
Tangible Book Value | 1,859 | 1,945 | 2,244 | 2,430 | 2,622 |
Tangible Book Value Per Share | 3.45 | 3.61 | 4.17 | 4.51 | 4.83 |
Buildings | - | 936.67 | 836.72 | 712.09 | 471.86 |
Machinery | - | 1,641 | 1,423 | 1,232 | 851.39 |
Construction In Progress | - | 457.86 | 695.78 | 736.4 | 922.19 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.